The USFDA has approved pacritinib to treat myelofibrosis, a rare bone marrow cancer. The drug belongs to the class of anti-inflammatory drugs known as Janus Kinase (JAK) inhibitors. It can compete with similar drugs approved for treating myelofibrosis in 2011 and 2019. FDA approval The approval was based on a study conducted on 63 patients suffering from intermediate or high-risk primary or secondary myelofibrosis and low platelet count.
They were given 200 mg of pacritinib twice daily. According to the findings, 29% of the patients showed 35% or greater spleen volume reduction compared to 3% of patients in the standard treatment group. Risks involved The common side effects of pacritinib are nausea, anemia, diarrhea, low platelet counts, and swelling in the legs. As this drug involves the risk of major bleeding, its intake should be avoided in patients with active bleeding and seven…
